AbbVie: all 2,243 studies

Page 16 of 23. Open to participants first (136), then studies with results posted, then the rest; newest registration first within each.

• A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food EffectCompletedNCT05486195Phase 1
• Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy ParticipantsTerminatedNCT05475821Phase 1
• Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerActive, not recruitingNCT05456685Phase 2
• A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the MouthCompletedNCT05454033Phase 3
• A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult ParticipantsCompletedNCT05452070Phase 3
• A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral UpadacitinibCompletedNCT05451316
• Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingNCT05445778Phase 3
• A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart ReviewCompletedNCT05444972
• Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASDCompletedNCT05439616Phase 3
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in CanadaTerminatedNCT05424562
• A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-UveitisCompletedNCT05414201Phase 4
• An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)CompletedNCT05411211
• Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle GlaucomaCompletedNCT05411198Phase 3
• Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDActive, not recruitingNCT05407636Phase 3
• To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal FunctionCompletedNCT05404542Phase 1
• To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCompletedNCT05404529Phase 1
• A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)CompletedNCT05394805
• An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing DupilumabCompletedNCT05394792
• Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic PresbyopiaWithdrawnNCT05393089Phase 2
• A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic ImpairmentTerminatedNCT05376839Phase 1
• Expanded Access to Bimatoprost (Durysta)No longer availableNCT05338606
• An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World PracticeCompletedNCT05327920
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in GreeceCompletedNCT05317494
• A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisWithdrawnNCT05316220Phase 3
• A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 TabletsActive, not recruitingNCT05308654Phase 1
• A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of RisankizumabCompletedNCT05305222Phase 1
• A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's DiseaseCompletedNCT05291234Phase 2
• A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in JapanActive, not recruitingNCT05286229Phase 1
• A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male ParticipantsCompletedNCT05283694Phase 1
• A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult ParticipantsCompletedNCT05283681Phase 1
• Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy ParticipantsCompletedNCT05274100Phase 1
• Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy VolunteersCompletedNCT05274087Phase 1
• A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in ChinaCompletedNCT05268068Phase 1
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05259839Phase 1
• Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With SchizophreniaCompletedNCT05245539Phase 1
• An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)WithdrawnNCT05217472Phase 2
• Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential TremorCompletedNCT05216250Phase 2
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax TabletsCompletedNCT05215639
• A Study of SDI-118 in Participants in Remission From DepressionWithdrawnNCT05212116Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive DeclineTerminatedNCT05199142Phase 1
• An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid ArthritisCompletedNCT05170646
• Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in ChinaActive, not recruitingNCT05144243Phase 4
• Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)CompletedNCT05141006Phase 2
• A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World SettingActive, not recruitingNCT05139836
• A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic TherapyActive, not recruitingNCT05139602Phase 2
• Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy ParticipantsCompletedNCT05123079Phase 1
• HArmonyCa Injectable Gel for Mid Face Soft Tissue AugmentationCompletedNCT05119777Phase 4
• Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy ParticipantsCompletedNCT05106309Phase 1
• A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world SettingActive, not recruitingNCT05094128
• Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's DiseaseCompletedNCT05094050Phase 1
• Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbital Hollowing in Chinese Adult ParticipantsCompletedNCT05088980Phase 3
• A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic DermatitisCompletedNCT05081557
• VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatment for FORehead Contouring and Marionette LinesCompletedNCT05077488Phase 4
• A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)CompletedNCT05029895
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabActive, not recruitingNCT05029882Phase 1
• A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn CapsulesTerminatedNCT05026502
• A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs AloneWithdrawnNCT04965272Phase 2
• Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) SymptomsCompletedNCT04949828
• A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral SclerosisTerminatedNCT04948645Phase 1
• Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromeTerminatedNCT04912063Phase 1
• Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple MyelomaTerminatedNCT04895410Phase 1
• Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative ColitisCompletedNCT04862741Phase 1
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977Active, not recruitingNCT04862286Phase 3
• A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving UpadacitinibCompletedNCT04846244
• RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT04832724Phase 2
• Expanded Access to Telisotuzumab VedotinTemporarily not availableNCT04830202
• Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)CompletedNCT04826523
• Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of MigraineCompletedNCT04818515Phase 1
• Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in TaiwanCompletedNCT04818385
• Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid LeukemiaCompletedNCT04813263
• Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal FunctionCompletedNCT04810598Phase 1
• Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer MetastasisTerminatedNCT04807972Phase 1
• Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersTerminatedNCT04804254Phase 1
• Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World SettingWithdrawnNCT04799990
• Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)CompletedNCT04799353Phase 1
• PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral DosingCompletedNCT04787302Phase 1
• Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of CareActive, not recruitingNCT04780516
• Open-label Trial in Parkinson's Disease (PD)CompletedNCT04760769Phase 3
• A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic ArthritisCompletedNCT04758117
• Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's DiseaseCompletedNCT04750226Phase 3
• A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)CompletedNCT04750213
• Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsActive, not recruitingNCT04721015Phase 1
• Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)CompletedNCT04721002
• Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDActive, not recruitingNCT04704921Phase 2/3
• A Study of JUVÉDERM VOLUX® Injectable Gel for Chin Enhancement in Chinese Adults Using Real-World EvidenceCompletedNCT04687046
• A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic MigraineCompletedNCT04686136Phase 3
• A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in BrazilWithdrawnNCT04666675Phase 3
• Evaluation of Age-related Skin Changes Using Clinical Probe Measurements and Imaging Modalities in Chinese SubjectsCompletedNCT04655300
• Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic LeukemiaTerminatedNCT04655261
• 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)CompletedNCT04647214
• Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)CompletedNCT04644120Phase 1
• Intradermal (ID) BOTOX in the Treatment of Facial Fine LinesCompletedNCT04631588Phase 1
• Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated PainCompletedNCT04630990
• A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, IllinoisCompletedNCT04611230
• A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy SubjectsCompletedNCT04592536Phase 1
• Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum DisorderCompletedNCT04578756Phase 3
• Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological ResponseCompletedNCT04577482
• A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT04574492
• Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT04570631Phase 1
• A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in CanadaWithdrawnNCT04567589

← AbbVie overview and focus areas